. 2020 Feb 7;16:381–396. doi: 10.2147/NDT.S203782

Table 1.

Interactions Between CBD and Other AEDs

Interacting AED	Effect of DDI on Other AEDs	Nature of Interaction		Possible Underlying Mechanisms
Interacting AED	Effect of DDI on Other AEDs	PK	PD	Possible Underlying Mechanisms
CLB	Non significant ↑[CLB]_PL (60%±80%); ↑↑↑[nCLB]_PL (500%±300%)	+	(+)	CBD-mediated inhibition of CYP2C19
Stiripentol	↑[Stiripentol]_PL (28–55%)	+		CBD-mediated inhibition of CYP2C19
VPA	Increased risk of ↑ transaminase levels and ↓PLTs	-	+	Unknown
TPM	↑[TPM]_PL (adults and children)	+		CBD-mediated inhibition of CYP2C19
RFD	↑[RFD]_PL (adults and children)	(+)		Unknown
ESL	↑[ESL]_PL (adults)	(+)		Unknown
ZNS	↑[ZNS]_PL (adults)	+		CBD-mediated inhibition of CYP3A4
BRV	↑[BRV]_PL (95–280%)	(+)		Unknown

Notes: The table shows only the effects of CBD on other AEDs (not vice versa). Possible (not properly demonstrated) interactions are indicated in brackets (). []_PL: plasmatic concentrations; ↑: increase; ↑↑↑: marked increase; ↓: decrease.

Abbreviations: AED, antiepileptic drug; BRV, Brivaracetam; CBD, cannabidiol; CLB, Clobazam; DDI, drug–drug interaction; ESL, Eslicarbazepine; nCLB, Norclobazam; PD, pharmacodynamics; PK, pharmacokinetics; PLTs, platelets; RFD, Rufinamide; TPM, Topiramate; VPA, Valproic Acid; ZNS, Zonisamide.